Argyrios Tzouvelekis, PhD
Research Awards Nationwide Recipient (2014-2016)
Funded by the American Lung Association of the Northeast
Enzyme Could Play Key Role in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease in which lung tissue becomes scarred over time in response to unknown injuries. This leads to shortness of breath and dry cough that gradually progresses, culminating in death in 3-5 years. The IPF lung is characterized by increases in cells in the lung called fibroblasts. We have discovered an enzyme called SHP-2 is decreased in the lung fibroblasts of patients with IPF. We will study whether reduced levels of SHP-2 from the lungs of patients with IPF render them susceptible to disease development, and whether restoring its levels in a mouse model of lung fibrosis may exert a therapeutic role.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.